Research Pipeline

Drug Pipeline Tracker

Every longevity compound in development — from bench to bedside. Visualize the full pipeline across stages, mechanisms, and categories.

Category

33 compounds|9 Preclinical6 Phase 113 Phase 23 Phase 32 Approved

← Swipe to see all stages →

Preclinical(9)

Rapalink-1

Keio University / various academic groupsmTOR

Bivalent mTOR inhibitor (rapamycin + Torin-1 linked)

Turn Bio RNA Reprogramming

Turn BiotechnologiesEpigenetic

mRNA-based transient Yamanaka factor expression

Altos Labs In Vivo Reprogramming

Altos LabsEpigenetic

In vivo partial epigenetic reprogramming

NewLimit Chromatin Remodeling

NewLimitEpigenetic

Chromatin state restoration via small molecules / gene therapy

Sierra Sciences Telomerase Activator

Sierra SciencesGene Therapy

hTERT promoter derepression (small molecule)

AgeX ProtoEmbryo / PureStem

AgeX TherapeuticsCell Therapy

Induced tissue regeneration (iTR); pluripotent-derived cells

Retro Biosciences Autophagy / Reprogramming

Retro BiosciencesCell Therapy

Autophagy enhancement + partial reprogramming

Acarbose

ITP / NIAMetabolic

Alpha-glucosidase inhibitor (CR mimetic)

Canagliflozin (SGLT2 inhibitor)

Janssen / NIA ITPMetabolic

SGLT2 inhibitor (glucose excretion; CR-like)

Phase 1(6)

AAV-OSK (Partial Reprogramming)

Rejuvenate Bio / David Sinclair LabEpigenetic

Partial Yamanaka factor (OSK) delivery via AAV

CRISPR-Telomerase (hTERT delivery)

Telomere Therapeutics / Progeria Research FoundationGene Therapy

AAV-CRISPR hTERT delivery

uCART-p16 (CAR-T Senolytic)

Agenus / Cold Spring Harbor LaboratoryCell Therapy

CAR-T cells targeting p16INK4a+ senescent cells

Recombinant Klotho

UCSF / Unity Through Knowledge FundHormonal

Klotho hormone supplementation

Recombinant GDF11

ElevianHormonal

TGF-β superfamily circulating factor

Calico / ABBV-CLS-484

Calico Life Sciences (Alphabet subsidiary)Other

Undisclosed aging target (immunological aging)

Phase 2(13)

RAD001 (Everolimus, aging dose)

NovartismTOR

Rapamycin analog (rapalog)

Rapamycin (longevity dosing)

Ora Biomedical / variousmTOR

mTORC1 inhibitor

UBX1325

Unity BiotechnologySenolytic

Bcl-xL inhibitor (senolytic)

Navitoclax

AbbVieSenolytic

Bcl-2/Bcl-xL/Bcl-w inhibitor

Dasatinib + Quercetin (D+Q)

Mayo Clinic / multiple investigator-sponsoredSenolytic

Tyrosine kinase inhibitor + flavonoid (senolytic combo)

Fisetin

Mayo Clinic (investigator-sponsored)Senolytic

Flavonoid senolytic / PI3K inhibitor

NMN (MIB-626)

Metro International Biotech / Washington UniversityNAD+

NAD+ precursor (NMN prodrug)

Apigenin + CD38 Inhibition

AgelessRx / University of ColoradoNAD+

CD38 inhibitor (spares NAD+)

Alpha-Ketoglutarate (CaAKG)

Ponce Health Sciences / BioAge LabsMetabolic

TCA cycle intermediate / histone demethylase cofactor

Intervene Immune Thymus Rejuvenation

Intervene ImmuneCell Therapy

Growth hormone + DHEA + metformin thymic regeneration

Alkahest GRF6019

Alkahest (Grifols subsidiary)Hormonal

Young plasma fraction (targeted protein components)

NuvOx NV-01 (Oxygen Therapeutic)

NuvOx PharmaOther

Dodecafluoropentane emulsion (oxygen delivery)

Spermidine (polyamine therapy)

TLL-Spermidine / Longevity Labs AustriaMetabolic

Autophagy inducer / polyamine

Phase 3(3)

Loyal LOY-001

LoyalHormonal

IGF-1 reduction (anti-aging via IGF-1 pathway)

Metformin (aging indication)

AFAR / NIA (TAME trial)Metabolic

AMPK activator / complex I inhibitor

Urolithin A (Mitopure)

AmazentisMetabolic

Mitophagy inducer

Approved(2)

NR (Niagen)

ChromaDexNAD+

NAD+ precursor (nicotinamide riboside)

TA-65 (Cycloastragenol)

T.A. Sciences / GeronGene Therapy

Telomerase activator (natural compound)

Legend: Headline drug — strongest data or most-watched trialPreclinicalPhase 1Phase 2Phase 3Approved